277 related articles for article (PubMed ID: 25924864)
1. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging.
Boeri M; Sestini S; Fortunato O; Verri C; Suatoni P; Pastorino U; Sozzi G
Expert Rev Mol Diagn; 2015 Jun; 15(6):801-13. PubMed ID: 25924864
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
[TBL] [Abstract][Full Text] [Related]
3. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer.
Tang D; Shen Y; Wang M; Yang R; Wang Z; Sui A; Jiao W; Wang Y
Eur J Cancer Prev; 2013 Nov; 22(6):540-8. PubMed ID: 23462458
[TBL] [Abstract][Full Text] [Related]
4. miR-Test: a blood test for lung cancer early detection.
Montani F; Marzi MJ; Dezi F; Dama E; Carletti RM; Bonizzi G; Bertolotti R; Bellomi M; Rampinelli C; Maisonneuve P; Spaggiari L; Veronesi G; Nicassio F; Di Fiore PP; Bianchi F
J Natl Cancer Inst; 2015 Jun; 107(6):djv063. PubMed ID: 25794889
[TBL] [Abstract][Full Text] [Related]
5. Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Boeri M; Pastorino U; Sozzi G
Cancer J; 2012; 18(3):268-74. PubMed ID: 22647364
[TBL] [Abstract][Full Text] [Related]
6. Serum and blood based biomarkers for lung cancer screening: a systematic review.
Chu GCW; Lazare K; Sullivan F
BMC Cancer; 2018 Feb; 18(1):181. PubMed ID: 29439651
[TBL] [Abstract][Full Text] [Related]
7. [Present Situation of Lung Cancer Screening Methods].
Zhang H; Zhang S
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):715-720. PubMed ID: 27760605
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.
Sozzi G; Boeri M; Rossi M; Verri C; Suatoni P; Bravi F; Roz L; Conte D; Grassi M; Sverzellati N; Marchiano A; Negri E; La Vecchia C; Pastorino U
J Clin Oncol; 2014 Mar; 32(8):768-73. PubMed ID: 24419137
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer screening: utility of molecular applications in conjunction with low-dose computed tomography guidelines.
Palma JF; Das P; Liesenfeld O
Expert Rev Mol Diagn; 2016; 16(4):435-47. PubMed ID: 26832450
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation.
Farooq M; Herman JG
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2416-2422. PubMed ID: 33148791
[TBL] [Abstract][Full Text] [Related]
11. [Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test].
Sestini S; Boeri M; Marchianò A; Silva M; Calareso G; Galeone C; Sozzi G; Pastorino U
Epidemiol Prev; 2016; 40(1 Suppl 1):42-50. PubMed ID: 26951732
[TBL] [Abstract][Full Text] [Related]
12. Current status of circulating protein biomarkers to aid the early detection of lung cancer.
Hirales Casillas CE; Flores Fernández JM; Padilla Camberos E; Herrera López EJ; Leal Pacheco G; Martínez Velázquez M
Future Oncol; 2014 Jun; 10(8):1501-13. PubMed ID: 25052758
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
14. The impact of genetic markers on the diagnosis of lung cancer: a current perspective.
Chorostowska-Wynimko J; Szpechcinski A
J Thorac Oncol; 2007 Nov; 2(11):1044-51. PubMed ID: 17975498
[TBL] [Abstract][Full Text] [Related]
15. [Lung screening].
Milleron B; Gounant V; Khalil A; Couraud S
Rev Pneumol Clin; 2017 Feb; 73(1):27-33. PubMed ID: 27956083
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing Lung Cancers through Examination of Micro-RNA Biomarkers in Blood, Plasma, Serum and Sputum: A Review and Summary of Current Literature.
Gyoba J; Shan S; Roa W; Bédard EL
Int J Mol Sci; 2016 Apr; 17(4):494. PubMed ID: 27043555
[TBL] [Abstract][Full Text] [Related]
17. Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.
Liu C; Xiang X; Han S; Lim HY; Li L; Zhang X; Ma Z; Yang L; Guo S; Soo R; Ren B; Wang L; Goh BC
Cancer Lett; 2022 Jan; 524():91-102. PubMed ID: 34656690
[TBL] [Abstract][Full Text] [Related]
18. Translating the transcriptome into tools for the early detection and prevention of lung cancer.
Gesthalter YB; Vick J; Steiling K; Spira A
Thorax; 2015 May; 70(5):476-81. PubMed ID: 25628310
[TBL] [Abstract][Full Text] [Related]
19. Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.
Powrózek T; Krawczyk P; Kowalski DM; Winiarczyk K; Olszyna-Serementa M; Milanowski J
Transl Res; 2015 Oct; 166(4):315-23. PubMed ID: 26079400
[TBL] [Abstract][Full Text] [Related]
20. Computed tomography screening for lung cancer: results of ten years of annual screening and validation of cosmos prediction model.
Veronesi G; Maisonneuve P; Rampinelli C; Bertolotti R; Petrella F; Spaggiari L; Bellomi M
Lung Cancer; 2013 Dec; 82(3):426-30. PubMed ID: 24099665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
